MX2024003258A - Inhibidores de ribonucleotido reductasa (rnr) de sulfonamida ciclica y usos de los mismos. - Google Patents

Inhibidores de ribonucleotido reductasa (rnr) de sulfonamida ciclica y usos de los mismos.

Info

Publication number
MX2024003258A
MX2024003258A MX2024003258A MX2024003258A MX2024003258A MX 2024003258 A MX2024003258 A MX 2024003258A MX 2024003258 A MX2024003258 A MX 2024003258A MX 2024003258 A MX2024003258 A MX 2024003258A MX 2024003258 A MX2024003258 A MX 2024003258A
Authority
MX
Mexico
Prior art keywords
rnr
inhibitors
ribonucleotide reductase
cyclic sulfonamide
sulfonamide
Prior art date
Application number
MX2024003258A
Other languages
English (en)
Spanish (es)
Inventor
Jacques Mauger
Anthony B Pinkerton
Stephen Todd Meyer
Yen Pham Hong Truong
Rachelle Janette Elsdon
Original Assignee
Boundless Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boundless Bio Inc filed Critical Boundless Bio Inc
Publication of MX2024003258A publication Critical patent/MX2024003258A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2024003258A 2021-09-17 2022-09-15 Inhibidores de ribonucleotido reductasa (rnr) de sulfonamida ciclica y usos de los mismos. MX2024003258A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163245718P 2021-09-17 2021-09-17
PCT/US2022/043660 WO2023043923A1 (en) 2021-09-17 2022-09-15 Cyclic sulfonamide ribonucleotide reductase (rnr) inhibitors and uses thereof

Publications (1)

Publication Number Publication Date
MX2024003258A true MX2024003258A (es) 2024-04-05

Family

ID=85603496

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024003258A MX2024003258A (es) 2021-09-17 2022-09-15 Inhibidores de ribonucleotido reductasa (rnr) de sulfonamida ciclica y usos de los mismos.

Country Status (11)

Country Link
US (1) US20250002486A1 (cg-RX-API-DMAC7.html)
EP (1) EP4401728A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024534420A (cg-RX-API-DMAC7.html)
KR (1) KR20240101555A (cg-RX-API-DMAC7.html)
CN (1) CN118434417A (cg-RX-API-DMAC7.html)
AU (1) AU2022345092A1 (cg-RX-API-DMAC7.html)
CA (1) CA3231660A1 (cg-RX-API-DMAC7.html)
IL (1) IL311458A (cg-RX-API-DMAC7.html)
MX (1) MX2024003258A (cg-RX-API-DMAC7.html)
TW (1) TW202328121A (cg-RX-API-DMAC7.html)
WO (1) WO2023043923A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112023002453A2 (pt) 2020-08-12 2023-05-02 Boundless Bio Inc Composições de agente de via de estresse de replicação e métodos para tratar câncer
EP4587437A1 (en) * 2022-09-13 2025-07-23 Boundless Bio, Inc. Cyclic sulfonamide ribonucleotide reductase (rnr) inhibitors and uses thereof
EP4770642A2 (en) * 2023-09-01 2026-07-08 Boundless Bio, Inc. Ribonucleotide reductase (rnr) compositions and methods of use

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2594799A (en) * 1998-02-11 1999-08-30 Du Pont Pharmaceuticals Company Novel cyclic sulfonamide derivatives as metalloproteinase inhibitors
WO2016189877A1 (en) * 2015-05-27 2016-12-01 Kyorin Pharmaceutical Co., Ltd. Urea derivative or pharmacologically acceptable salt thereof
ES2982299T3 (es) * 2016-05-31 2024-10-15 Taiho Pharmaceutical Co Ltd Compuestos de sulfonamida o sal de los mismos como inhibidores de ribonucleótido reductasa para el tratamiento del cáncer
TWI748142B (zh) * 2017-11-29 2021-12-01 日商大鵬藥品工業股份有限公司 抗腫瘤劑
AU2018377036B2 (en) * 2017-11-29 2022-04-14 Taiho Pharmaceutical Co., Ltd. Sulfonamide compounds and use thereof
MA56065A (fr) * 2019-05-29 2022-04-06 Taiho Pharmaceutical Co Ltd Polythérapie anticancéreuse mettant en oeuvre un composé de sulfonamide et un immunomodulateur
EP4301735A4 (en) * 2021-03-02 2025-05-21 Boundless Bio, Inc. Ribonucleotide reductase (rnr) inhibitors and uses thereof

Also Published As

Publication number Publication date
EP4401728A1 (en) 2024-07-24
IL311458A (en) 2024-05-01
US20250002486A1 (en) 2025-01-02
KR20240101555A (ko) 2024-07-02
WO2023043923A1 (en) 2023-03-23
JP2024534420A (ja) 2024-09-20
CA3231660A1 (en) 2023-03-23
EP4401728A4 (en) 2025-08-06
TW202328121A (zh) 2023-07-16
CN118434417A (zh) 2024-08-02
AU2022345092A1 (en) 2024-04-04

Similar Documents

Publication Publication Date Title
MX2021013788A (es) Dosificación del inhibidor de kras para el tratamiento de cánceres.
MX2024002561A (es) Combinaciones farmaceuticas que comprenden un inhibidor de tead y usos de las mismas para el tratamiento de canceres.
CO2026004333A2 (es) Inhibidores de ras-pi3k para el tratamiento del cáncer y enfermedades inmunológicas
MX2024001894A (es) Compuestos heterociclicos y metodos de uso.
MX2023000735A (es) Metodos y combinaciones de inhibidor de kat6 para el tratamiento del cancer.
CL2024003040A1 (es) Tratamientos del cáncer con inhibidores de prmt5 cooperativos con mta
MX2021009269A (es) Inhibidores de enpp1 y metodos para modular una respuesta inmunitaria.
MX394252B (es) Tratamiento del cancer usando combinaciones de inhibidores de erk y raf
MX2024009943A (es) Inhibidores de arn helicasa dhx9 y usos de los mismos
MX2016004580A (es) Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia.
MX381890B (es) Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para uso en el tratamiento de tumores solidos
PE20120998A1 (es) Metodos para el tratamiento del cancer usando antagonistas de notch
CL2020000270A1 (es) Combinación terapéutica de un inhibidor tirosina quinasa del egfr de tercera generación y un inhibidor raf.
ECSP19056271A (es) Dendrímeros terapéuticos
CL2022003511A1 (es) Inhibidores de alk2 para el tratamiento de la anemia.
MX2013008012A (es) Tratamiento para la lipodistrofia.
MX385122B (es) Uso de ibrutinib en el tramiento de enfermedad injerto contra huésped crónica.
MX2019003134A (es) Terapia de combinacion.
MX2022014792A (es) Cocristales, composiciones farmaceuticas de los mismos y metodos de tratamiento que los implican.
CL2022003039A1 (es) Inhibidores de il4i1 y métodos de uso.
MX2022006500A (es) Terapia de combinacion que involucra compuestos macrociclicos de diarilo.
CL2021003032A1 (es) Métodos de tratamiento de la urticaria crónica espontánea utilizando un inhibidor de la tirosina quinasa de bruton
DOP2013000131A (es) Composiciones y métodos para tratar el cáncer usando un inhibidor de pi3k y un inhibidor de mek
CO2025003263A2 (es) Inhibidores de kif18a y usos de estos
CL2022001872A1 (es) Inhibidores de ahr y usos de los mismos